SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing significant upward momentum fueled by reports of major insider and political stock purchases alongside a reinstated buy rating from BofA. Community sentiment is overwhelmingly bullish, with many traders discussing a rotation from hardware into software and positioning for a potential squeeze as the stock reclaims key technical levels.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility driven by a broader semiconductor sell-off and investor concerns over memory industry capacity, despite analysts recently raising price targets citing robust demand for AI infrastructure. The community remains sharply divided, with many retail investors viewing the pullback as a buying opportunity while others express anxiety over macro headwinds and potential sector overextension.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether its current valuation reflects a deep-value opportunity or a value trap, with the community closely tracking its pivot into agentic AI orchestration and enterprise integration partnerships. While many participants express frustration over persistent share price weakness and perceived market manipulation, others are aggressively accumulating shares, pointing to the company's strong cash position, lack of debt, and potential for long-term growth as the market rotates toward quality AI software.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending as investors digest a string of beat-and-raise earnings reports and an emerging partnership with OpenAI, while community discussions highlight a sharp divide between those holding for long-term growth and those frustrated by persistent selling pressure and share-based compensation. Sentiment remains split between retail investors eager for a breakout toward higher price targets and short-term traders attempting to capitalize on the stock's cyclical volatility and recent liquidity events.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant volatility and high trading volume as investors debate its valuation relative to larger semiconductor testing peers. The community is sharply divided, with some highlighting recent contract wins and capacity expansion as signs of a long-term rerating, while others caution against the stock's parabolic move and potential for a sharp reversal.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is currently trending as investors weigh its long-term growth potential in AI-powered defense systems and autonomous drone warfare against recent volatility and sector-wide de-risking. The community is actively debating the company's competitive moats, the impact of federal budget allocations for unmanned systems, and whether current price levels represent an accumulation opportunity for a key player in modern military technology.

Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA.

Agilysys, Inc

Agilysys is trending following a strong quarterly earnings report that featured a revenue beat and upward-revised forward guidance, fueling investor confidence in its subscription model and enterprise technology. The community is actively discussing the company's growth trajectory and momentum within the hospitality software sector, with many participants monitoring the stock for potential breakouts.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is currently trending as the community scrutinizes recent clinical data releases and the company's long-term competitive position, with some investors debating its potential for future growth against broader market volatility.

Lakeland Industries, Inc. engages in the manufacture and sale of safety garments and accessories for the industrial and public protective clothing market. It operates through the Domestic and International geographical segments. The firm's products include disposable protective clothing, chemical protective clothing, woven protective clothing, fire protective gear, heat protective clothing, reflective protective clothing, hand and arm protection, arc or fire-retardant rated rainwear, and fire-retardant protective clothing. The company was founded in April 1982 and is headquartered in Huntsville, AL.

Lakeland Industries, Inc.

Lakeland Industries is trending as investors monitor potential demand for protective equipment amid rising concerns over global health outbreaks. Community discussion centers on the company's historical performance during past pandemics and ongoing speculation regarding whether current health trends will catalyze a surge in demand for its PPE products.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is attracting significant investor attention following a notable stock purchase by its CEO, signaling internal confidence as the company navigates a strategic pivot toward stablecoin and AI-driven payment infrastructure. While the community remains divided between skepticism over past performance and optimism regarding potential regulatory tailwinds, many are actively monitoring the stock for a possible breakout driven by its evolving business model and institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals signal momentum with caution.read more...

Best Small Cap Stocks To Keep An Eye On - May 4th

Direxion Daily MU Bull 2X Shares, Inflection Point Acquisition Corp. II, CNS Pharmaceuticals, Critical Metals, Elong Power, Direxion Daily PLTR Bear 1X Shares, and Spring Valley Acquisition are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stock...

Medical Stocks To Watch Today - May 4th

Arcellx, Eli Lilly and Company, UnitedHealth Group, CNS Pharmaceuticals, and Johnson & Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare including pharmaceuticals, biotec...

Pharmaceutical Stocks To Follow Today - May 4th

Eli Lilly and Company, CNS Pharmaceuticals, Novo Nordisk A/S, Abbott Laboratories, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell...

Institutional Giants Are Piling into Four of These NASDAQ Plays

The market is currently seeing a flurry of activity as companies across the biotech and technology sectors secure substantial funding and execute strategic transformations. $CNSP, $KBLB, $PN, $RLYB, $ADVB, $CLNN, $CABA

<ul class="summary-bullets"><li>CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology.</li><li>The company is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.</li><li>The biotech firm will look to acquire or license preclinical and clinical-stage assets with clear development paths and strong commercial potential.</li></ul>Shares of CNS Pharmaceuticals Inc. (CNSP) rocketed over 330% in early trade on Monday, registering their biggest ever single-day gains since implementing a 1-for-12 reverse stock split last July, as investors cheered a $22.5 million private placement to boost its acquisition strategy.The financing includes participation from institutional healthcare investors such as ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners.The private placement involves the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares. CNSP shares closed at $2.31 on Friday.“With the proceeds from this financing, the company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years,” said Rami Levin, President and CEO of CNS Pharmaceuticals.<h2 class="st-heading-2">Strategic Shift Toward Acquisitions, Licensing</h2>CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology. The company is prioritizing assets with clear development paths, strong scientific backing, and near-term catalysts.At the same time, the firm is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.In March, CNS Pharmaceuticals <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-oncology-pipeline/">announced</a> a new growth strategy focused on building a strong pipeline in neurology and oncology. The biotech firm will look to acquire or license preclinical and clinical-stage assets, prioritizing programs with clear development paths and strong commercial potential.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CNSP">CNSP</a> on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user saw $11 to $12 as a key resistance level.<stembedurl>https://stocktwits.com/cjstocksup/message/652162741</stembedurl>However, another user expects the stock to drop “hard.”<stembedurl>https://stocktwits.com/belikemike7/message/652165417</stembedurl>The stock is up 70% year-to-date.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-xndu-stock-down-today-xanadu-quantum-share-registration/cZQMsDAReJ4">XNDU Stock Crashed 68%, But It’s Not A New Offering – Retail Traders Call It An ‘Overreaction’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Why Did CNSP Stock Surge 330% Today?

The company announced a private placement, involving the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares.

Equity

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals announces $22.5 million financing as the company pivots its strategy, eyes asset acquisitions.read more...

CNS Pharmaceuticals Secures $22.5 M in Oversubscribed Private Placement

CNS Pharmaceuticals (NASDAQ:CNSP) significantly boosted its capital reserves, entering into securities purchase agreements for a private placement expected to generate $22.5 million in gross proceeds.

Shares of CNS Pharmaceuticals, Inc. (CNSP) declined 5% on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-second-line-treatment-of-glioblastoma-multiforme-44471506">reported </a>wider losses in the first quarter (Q1).The firm’s net loss for the three months ended March 31, 2025, was approximately $4.3 million, compared to approximately $3.5 million for the comparable period in 2024.The company said the increase in net loss is largely attributable to the costs of data clean-up, preparation, and analysis for the topline primary data release on the Berubicin trial in brain cancer.CNS Pharmaceuticals’ research and development expenses rose to $3.2 million in the quarter, while general and administrative expenses fell marginally to $1.09 million, owing to a decrease in stock-based compensation, marketing, advertising, and insurance expenses.The company ended the quarter with cash of approximately $13.1 million. CNS believes that the cash on hand as of March 31, 2025, in addition to the $5 million raised from a public offering earlier this month, is sufficient to fund planned operations into the second half of 2026.CNS is developing treatments for cancers in the brain and central nervous system. By year-end, the company intends to commence the phase 2 study of its lead program, TPI 287, for treating Glioblastoma Multiforme (GBM). Glioblastoma multiforme (GBM) is the most common form of cancer that originates in the brain.On Stocktwits, retail sentiment around CNSP remained ‘extremely bullish’ over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_9_01_42_AM_png_cf9bcf9c43.webp" alt="CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CNSP">CNSP stock</a> is down by 80% this year and over 99% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.

This account has been verified as an official CNSP representative.

Verified Account

CNS Pharma

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Current Price	$4.71
Prev Close	$4.95
Open	$5.00
Dividend Yield	0.00%
50-Day Moving Average	$3.31
Beta	1.04
Avg. Volume	24,734.92
PE Ratio	-0.16

52-Week High	$16.56
52-Week Low	$1.90
Market Capitalization	$7.23M
EPS (Annual)	-$35.75
Price to Book	54.06
Revenue Per Employee	$0.00

CNSP
Cns Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CNSP News

CNSPCns Pharmaceuticals Inc